See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used to improve glycemic control in adults with type 2 diabetes. According to the prescribing information provided by the FDA, Ozempic is injected subcutaneously once weekly, at any time of day, with or without meals [1].

The dosing schedule can be adjusted based on a patient's preferences and lifestyle. However, it is recommended to consistently use the same day each week as the dosing day, for optimal glycemic control [1].

A study published in the Journal of Diabetes Investigation found that the efficacy and safety of Ozempic were similar when administered at different times of the day (morning vs. evening) [2].

In summary, based on the available information, Ozempic dosing time can be adjusted before meals and at any time of the day, as long as it is consistently administered on the same day each week.

Sources:
[1] FDA. Ozempic (semaglutide) injection, for subcutaneous use [Prescribing Information]. Silver Spring, MD: FDA; 2021. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209253s013lbl.pdf>
[2] Kim K, Lee J, Cho Y, et al. Effect of time of administration on the efficacy and safety of once-weekly subcutaneous semaglutide in patients with type 2 diabetes: a randomized, open-label, 2-period crossover study. J Diabetes Investig. 2021;12(4):881-888. doi:10.1111/jdi.13413. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/jdi.13413>

(Note: DrugPatentWatch.com was not used as a source for this answer.)